Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.60 |
| ▸ | CYP46A1 | Q9Y6A2 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.60 |
| ▸ | OSBP | P22059 | 1/20 | 0.60 |
| ▸ | RORC | P51449 | 1/20 | 0.60 |
| ▸ | OSBP2 | Q969R2 | 1/20 | 0.60 |
| ▸ | POLA1 | P09884 | 1/20 | 0.57 |
| ▸ | GRIN1 | Q05586 | 12/20 | 0.56 |
| ▸ | GRIN2B | Q13224 | 12/20 | 0.56 |
| ▸ | GRIN2A | Q12879 | 10/20 | 0.55 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19692309 | 1.00 | USP2 (0.60) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL19691912 | 0.92 | USP2 (0.60) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL3359948 | 0.92 | USP2 (0.60) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL1050027 | 0.91 | USP2 (0.59) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL22658123 | 0.91 | USP2 (0.59) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL8205164 | 0.91 | USP2 (0.59) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL1081197 | 0.91 | USP2 (0.59) | USP2CYP46A1LMNAABCB1OSBP | |
| Hydrochloric Acid SCHEMBL11907786 | 0.91 | USP2 (0.58) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL18797660 | 0.91 | USP2 (0.58) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL2440566 | 0.91 | OSBP (0.58) | USP2CYP46A1LMNAABCB1OSBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022255701-A1 | LIPOPROTEIN-MIMICKING SOLID LIPID NANOPARTICLES FOR DRUG DELIVERY AND USES THEREOF | 주식회사 티온랩테라퓨틱스 | 2022-12-08 | — | — | WO | claimed |
| EP-3357491-B1 | PHARMACEUTICAL COMPOSITION FOR DELIVERING AN ANIONIC DRUG | SAMYANG BIOPHARMACEUTICALS (KR) | 2021-06-02 | — | — | EP | claimed |
| US-20210077406-A1 | COMPOSITION AND METHOD FOR FREEZE-DRYING PHARMACEUTICAL COMPOSITION CONTAINING ANIONIC DRUG | SAMYANG BIOPHARMACEUTICALS CORPORATION (KR) | 2021-03-18 | — | — | US | claimed |
| EP-2833869-B1 | METHOD OF PREPARING COMPOSITION FOR DELIVERING AN ANIONIC DRUG | SAMYANG BIOPHARMACEUTICALS (KR) | 2020-10-28 | — | — | EP | claimed |
| US-10292932-B2 | Polymeric micelle particle comprising anionic drugs and method of preparing the same | SAMYANG BIOPHARMACEUTICALS CORPORATION (KR) | 2019-05-21 | — | — | US | claimed |
| US-20180250409-A1 | PHARMACEUTICAL COMPOSITION CONTAINING ANIONIC DRUG, AND PREPARATION METHOD THEREFOR | SAMYANG BIOPHARMACEUTICALS CORPORATION (KR) | 2018-09-06 | — | — | US | claimed |
| EP-3357491-A1 | PHARMACEUTICAL COMPOSITION CONTAINING ANIONIC DRUG, AND PREPARATION METHOD THEREFOR | Samyang Biopharmaceuticals Corporation (KR) | 2018-08-08 | — | — | EP | claimed |
| EP-2217221-B1 | LDL-LIKE CATIONIC NANOPARTICLES FOR DELIVERYING NUCLEIC ACID GENE, METHOD FOR PREPARING THEREOF AND METHOD FOR DELIVERYING NUCLEIC ACID GENE USING THE SAME | KOREA ADVANCED INST SCI & TECH (KR) | 2018-06-27 | — | — | EP | claimed |
| US-10004694-B2 | Targeted poorly water-soluble drug delivery system, method of preparing the same, and pharmaceutical composition including the same | SAMSUNG LIFE PUBLIC WELFARE FOUNDATION (KR) | 2018-06-26 | — | — | US | claimed |
| US-9439856-B2 | Method of preparing composition for delivering an anionic drug | SAMYANG BIOPHARMACEUTICALS CORPORATION (KR) | 2016-09-13 | — | — | US | claimed |
| US-9439858-B2 | Temperature sensitive liposome including cationic lipid and use thereof | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2016-09-13 | — | — | US | claimed |
| US-20160228361-A1 | POLYMERIC MICELLE PARTICLE COMPRISING ANIONIC DRUGS AND METHOD OF PREPARING THE SAME | SAMYANG HOLDINGS CORPORATION (KR) | 2016-08-11 | — | — | US | claimed |
| US-20150328152-A1 | Method of Preparing Composition for Delivering an Anionic Drug | SAMYANG HOLDINGS CORPORATION (KR) | 2015-11-19 | — | — | US | claimed |
| US-20150297749-A1 | LOW-DENSITY LIPOPROTEIN ANALOGUE NANOPARTICLES, AND COMPOSITION COMPRISING SAME FOR TARGETED DIAGNOSIS AND TREATMENT OF LIVER | POSTECH ACADEMY-INDUSTRY FOUNDATION (KR) | 2015-10-22 | — | — | US | claimed |
| US-20110268772-A1 | PHARMACEUTICAL COMPOSITION CONTAINING AN ANIONIC DRUG AND A PRODUCTION METHOD THEREOF | SAMYANG CORPORATION (KR) | 2011-11-03 | — | — | US | claimed |
| EP-2377517-A2 | PHARMACEUTICAL COMPOSITION CONTAINING AN ANIONIC DRUG, AND A PRODUCTION METHOD THEREFOR | Samyang Corporation (KR) | 2011-10-19 | — | — | EP | claimed |
| JP-2011500671-A | — | — | 2011-01-06 | — | — | JP | claimed |
| US-20100297242-A1 | LDL-LIKE CATIONIC NANOPARTICLES FOR DELIVERYING NUCLEIC ACID GENE, METHOD FOR PREPARING THEREOF AND METHOD FOR DELIVERYING NUCLEIC ACID GENE USING THE SAME | SAMYANG BIOPHARMACEUTICALS CORPORATION (KR) | 2010-11-25 | — | — | US | claimed |
| EP-2217221-A2 | LDL-LIKE CATIONIC NANOPARTICLES FOR DELIVERYING NUCLEIC ACID GENE, METHOD FOR PREPARING THEREOF AND METHOD FOR DELIVERYING NUCLEIC ACID GENE USING THE SAME | Korea Advanced Institute of Science and Technology (KR) | 2010-08-18 | — | — | EP | claimed |
| WO-2009051451-A2 | LDL-LIKE CATIONIC NANOPARTICLES FOR DELIVERYING NUCLEIC ACID GENE, METHOD FOR PREPARING THEREOF AND METHOD FOR DELIVERYING NUCLEIC ACID GENE USING THE SAME | KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2009-04-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210077406-A1 | COMPOSITION AND METHOD FOR FREEZE-DRYING PHARMACEUTICAL COMPOSITION CONTAINING ANIONIC DRUG | ANXA6, PHOSPHO1, ABHD16A | USP2 2958/4885CYP46A1 1509/4885LMNA 3154/4885 |
| US-10004694-B2 | Targeted poorly water-soluble drug delivery system, method of preparing the same, and pharmaceutical composition including the same | CD44, TP53, ASGR1 | USP2 495/4885CYP46A1 891/4885LMNA 4255/4885 |
| US-20150328152-A1 | Method of Preparing Composition for Delivering an Anionic Drug | LIPA, APOB, CETP | USP2 3027/4885CYP46A1 102/4885LMNA 216/4885 |
| US-20180250409-A1 | PHARMACEUTICAL COMPOSITION CONTAINING ANIONIC DRUG, AND PREPARATION METHOD THEREFOR | THEM6, NOTUM, CETP | USP2 4415/4885CYP46A1 32/4885LMNA 1750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.